



Effective Health Care Curcumin for Treatment of Newly Diagnosed Hodgkin's Lymphoma Nomination Summary Document

Results of Topic Selection Process & Next Steps

- Curcumin for treatment of newly diagnosed Hodgkin's lymphoma is not feasible for a full systematic review due to the limited data available at this time.

Topic Description

Nominator: Organization

Nomination Summary: For patients with classical Hodgkin lymphoma (HL), the nominator questions the comparative effectiveness of standard chemotherapy versus inhibitors of activated signaling pathways (such as Jak-STAT). Specifically, the nominator is interested in curcumin, a polyphenolic compound found in the spice turmeric.

Staff-Generated PICO

Population(s): Patients between the ages of 10 and 80 with newly diagnosed Hodgkin lymphoma, nodular sclerosis (NS) subtype

Intervention(s): Inhibitors of activated signaling pathways (e.g., curcumin) plus radiation therapy

Comparator(s): Standard Chemotherapy (doxorubicin [Adriamycin®], bleomycin, vinblastine, and dacarbazine (ABVD) plus radiation therapy

Outcome(s): Reduction of tumor burden, improvements in B symptoms (fever, night sweats, weight loss), secondary malignancies, adverse effects

Key Questions from Nominator: 1. For patients with classical Hodgkin lymphoma (HL), what is the comparative effectiveness of standard chemotherapy versus inhibitors of activated signaling pathways (such as Jak-STAT)?

Considerations

- The topic meets some EHC Program appropriateness and importance criteria. (For more information, see <http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/how-are-research-topics-chosen/>.)
- Curcumin is not available as a therapeutic agent for any disease in the US. As such, there are no existing guidelines for treatment of Hodgkin's lymphoma with curcumin. No studies of Hodgkin's lymphoma have been designed to preclude one or more treatment groups of standard chemotherapy since the current standard treatment is 80% effective. While there are a number of clinical trials on curcumin and cancer, none are focused on the nominator's disease of interest. Therefore, this topic is not feasible for a full systematic review due to the limited data available for a review at this time.